Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adam Zamecnik


London, UK

Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.

Latest From Adam Zamecnik

Sawai Reports Slight Growth In Japan Amid Challenges

The company’s third quarter results come during its planned withdrawal from the US and the recent implementation of administrative dispositions in Japan on grounds of GMP violations.

Sales & Earnings Manufacturing

Generics Are 45% Cheaper In Canada Than In 11 Key Markets

Despite increased pressures from inflation and dependence on international supply chains, the average cost of generics in Canada is 45% lower than in 11 comparator countries, the CGPA reports.

Pricing Debate Generic Drugs

Lupin Reports Near 300% Profit Growth Coupled With Launches

The Indian generics manufacturer has reported a nearly 300% year-on-year growth in profits in Q3, as it starts to see the impact of its Spiriva generic’s launch in the US.

Sales & Earnings Generic Drugs

Private Equity Firm Acquires Irish Generics Player Chanelle

The private equity firm Exponent has acquired Ireland’s biggest generics producer, Chanelle Pharma, following past media reports of the pharma’s nearing sale, which estimated the price north of €300m.

Deals M & A

Hikma Launches Combined Pain Relief Drug Combogesic IV In US

Hikma announced the launch of the pain relief solution in the US where it will be sold under the name Combogesic IV as part of a deal with Hyloris Pharmaceuticals.

Launches Value-Added Medicines

Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

Biosimilars Clinical Trials
See All